148 related articles for article (PubMed ID: 21314250)
1. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole.
Michallet M; Sobh M; Morisset S; Kraghel S; Nicolini FE; Thomas X; Bienvenu AL; Picot S; Nicolle MC; Vanhems P
Med Mycol; 2011 Oct; 49(7):681-7. PubMed ID: 21314250
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia.
Le Clech L; Uguen M; Quinio D; Nevez G; Couturier MA; Ianotto JC; Berthou C; Guillerm G; Le Bars H; Payan C; Narbonne V; Baron R; Saliou P
Curr Res Transl Med; 2020 Jan; 68(1):23-28. PubMed ID: 31787568
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia.
Desplanques PY; Burlacu R; Poinsignon V; Boussion H; Borget I; Wyplosz B; de Botton S; Billaud E; Chachaty E; Gachot B; Netzer F; Micol JB
Med Mal Infect; 2014 Apr; 44(4):174-9. PubMed ID: 24656841
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
7. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
[TBL] [Abstract][Full Text] [Related]
8. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia.
Myoken Y; Sugata T; Kyo T; Fujihara M; Mikami Y
J Periodontol; 2002 Jan; 73(1):33-8. PubMed ID: 11846198
[TBL] [Abstract][Full Text] [Related]
9. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
[TBL] [Abstract][Full Text] [Related]
10. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
[TBL] [Abstract][Full Text] [Related]
12. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
13. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.
Chong GL; Broekman F; Polinder S; Doorduijn JK; Lugtenburg PJ; Verbon A; Cornelissen JJ; Rijnders BJ
Int J Antimicrob Agents; 2015 Jul; 46(1):82-7. PubMed ID: 25956843
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.
Bourdelin M; Grenouillet F; Daguindau E; Muret P; Desbrosses Y; Dubut J; Deconinck E; Limat S; Larosa F
Med Mycol; 2014 Oct; 52(7):728-35. PubMed ID: 25012993
[TBL] [Abstract][Full Text] [Related]
15. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
16. [Itraconazole 800 mg for the prophylaxis of fungal infections in patients with acute leukemia and severe neutropenia].
Andrade M A; Puga L B; Guerra C C; Molina E J; Capurro C M
Rev Med Chil; 2011 Sep; 139(9):1128-34. PubMed ID: 22215390
[TBL] [Abstract][Full Text] [Related]
17. Invasive aspergillosis in children with acute leukemia at a resource-limited oncology center.
Jain S; Kapoor G
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e1-5. PubMed ID: 24686246
[TBL] [Abstract][Full Text] [Related]
18. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
20. Estimation of the incubation period of invasive aspergillosis by survival models in acute myeloid leukemia patients.
Bénet T; Voirin N; Nicolle MC; Picot S; Michallet M; Vanhems P
Med Mycol; 2013 Feb; 51(2):214-8. PubMed ID: 22662757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]